FindTrial
Sign In

Medical records based study for the efficiency and safety for large dose esomeprazole in cirrhotic patients with variceal hemorrhage

Medical records based study for the efficiency and safety for large dose esomeprazole in cirrhotic patients with variceal hemorrhage

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029299
Enrollment
Unknown
Registered
2020-01-22
Start date
2020-01-12
Completion date
Unknown
Last updated
2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal variceal bleeding in patients with liver cirrhosis

Interventions

large dose esomeprazole group:Esomeprazole 8mg/h (192mg/day) continuous intravenous drip
Conventional dose group:standard PPI, bid

Sponsors

Shenzhen People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) 18 to 75 years of age; (2) the diagnosis of upper gastrointestinal hemorrhage on admission; (3) treated with intravenous proton pump inhibitors after admission.

Exclusion criteria

Exclusion criteria: (1) bleeding from sources different to cirrhosis or portal hypertension gastropathy; (2) recent use of glucocorticoid in patients with severe diseases of the immune system.

Design outcomes

Primary

MeasureTime frame
further bleeding in 30 days;—

Secondary

MeasureTime frame
blood transfusion;Hospitalization days;mortality;—

Countries

China

Contacts

Public ContactLi Kuan

Shenzhen People's Hospital

li_kuan1989@126.com+86 13469973955

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 24, 2026